Decentralizing gene and cell therapy manufacturing: changing tides or uphill battle

Cell & Gene Therapy Insights 2024; 10(8), 1247–1251

DOI: 10.18609/cgti.2024.141

Published: 4 October
Viewpoint
Magdi Elsallab



“A concerted effort must be made to decentralize manufacturing, particularly for autologous products, and to adapt the regulatory framework to reflect the unique nature of [cell and gene] therapies.”